172 related articles for article (PubMed ID: 37112982)
1. Discovery of Highly Potent Small Molecule Pan-Coronavirus Fusion Inhibitors.
Curreli F; Chau K; Tran TT; Nicolau I; Ahmed S; Das P; Hillyer CD; Premenko-Lanier M; Debnath AK
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112982
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays.
Curreli F; Ahmed S; Victor SMB; Drelich A; Panda SS; Altieri A; Kurkin AV; Tseng CK; Hillyer CD; Debnath AK
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062273
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
[TBL] [Abstract][Full Text] [Related]
4. Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics.
Pérez-Vargas J; Shapira T; Olmstead AD; Villanueva I; Thompson CAH; Ennis S; Gao G; De Guzman J; Williams DE; Wang M; Chin A; Bautista-Sánchez D; Agafitei O; Levett P; Xie X; Nuzzo G; Freire VF; Quintana-Bulla JI; Bernardi DI; Gubiani JR; Suthiphasilp V; Raksat A; Meesakul P; Polbuppha I; Cheenpracha S; Jaidee W; Kanokmedhakul K; Yenjai C; Chaiyosang B; Teles HL; Manzo E; Fontana A; Leduc R; Boudreault PL; Berlinck RGS; Laphookhieo S; Kanokmedhakul S; Tietjen I; Cherkasov A; Krajden M; Nabi IR; Niikura M; Shi PY; Andersen RJ; Jean F
Antiviral Res; 2023 Jan; 209():105484. PubMed ID: 36503013
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.
Xia S; Wang L; Jiao F; Yu X; Xu W; Huang Z; Li X; Wang Q; Zhu Y; Man Q; Jiang S; Lu L
Emerg Microbes Infect; 2023 Dec; 12(1):2178241. PubMed ID: 36748716
[TBL] [Abstract][Full Text] [Related]
6. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
[TBL] [Abstract][Full Text] [Related]
7. Transchromosomic bovines-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1, and influenza A virus.
Saied AA; Nascimento MSL; do Nascimento Rangel AH; Skowron K; Grudlewska-Buda K; Dhama K; Shah J; Abdeen A; El-Mayet FS; Ahmed H; Metwally AA
J Med Virol; 2022 Oct; 94(10):4599-4610. PubMed ID: 35655326
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity.
Khatri R; Siddqui G; Sadhu S; Maithil V; Vishwakarma P; Lohiya B; Goswami A; Ahmed S; Awasthi A; Samal S
Med Microbiol Immunol; 2023 Feb; 212(1):103-122. PubMed ID: 36583790
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron.
Zhu Y; Dong X; Liu N; Wu T; Chong H; Lei X; Ren L; Wang J; He Y
Emerg Microbes Infect; 2022 Dec; 11(1):1819-1827. PubMed ID: 35786417
[TBL] [Abstract][Full Text] [Related]
10. High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1.
Kuzikov M; Woens J; Zaliani A; Hambach J; Eden T; Fehse B; Ellinger B; Riecken K
Biomed Pharmacother; 2022 Jul; 151():113104. PubMed ID: 35643072
[TBL] [Abstract][Full Text] [Related]
11. A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants.
Pérez-Vargas J; Worrall LJ; Olmstead AD; Ton AT; Lee J; Villanueva I; Thompson CAH; Dudek S; Ennis S; Smith JR; Shapira T; De Guzman J; Gang S; Ban F; Vuckovic M; Bielecki M; Kovacic S; Kenward C; Hong CY; Gordon DG; Levett PN; Krajden M; Leduc R; Boudreault PL; Niikura M; Paetzel M; Young RN; Cherkasov A; Strynadka NCJ; Jean F
Emerg Microbes Infect; 2023 Dec; 12(2):2246594. PubMed ID: 37555275
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY
Antiviral Res; 2023 Jun; 214():105609. PubMed ID: 37086978
[TBL] [Abstract][Full Text] [Related]
13. Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
Zhu Y; Hu Y; Liu N; Chong H; He Y
Antiviral Res; 2022 Dec; 208():105445. PubMed ID: 36265805
[TBL] [Abstract][Full Text] [Related]
14. Investigation on the interaction mechanism of different SARS-CoV-2 spike variants with hACE2: insights from molecular dynamics simulations.
Wu J; Zhang HX; Zhang J
Phys Chem Chem Phys; 2023 Jan; 25(3):2304-2319. PubMed ID: 36597957
[TBL] [Abstract][Full Text] [Related]
15. Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern.
Vanhulle E; D'huys T; Provinciael B; Stroobants J; Camps A; Noppen S; Schols D; Van Damme EJM; Maes P; Stevaert A; Vermeire K
Front Cell Infect Microbiol; 2022; 12():989534. PubMed ID: 36111239
[No Abstract] [Full Text] [Related]
16. Antibody cocktail effective against variants of SARS-CoV-2.
Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
[TBL] [Abstract][Full Text] [Related]
17. An enhanced broad-spectrum peptide inhibits Omicron variants in vivo.
Bi W; Tang K; Chen G; Xie Y; Polizzi NF; DeGrado WF; Yuan S; Dang B
Cell Rep Med; 2024 Feb; 5(2):101418. PubMed ID: 38340726
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
[TBL] [Abstract][Full Text] [Related]
19. Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants.
Bi W; Chen G; Dang B
J Virol; 2022 Jul; 96(13):e0068122. PubMed ID: 35735997
[TBL] [Abstract][Full Text] [Related]
20. The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants.
Gellenoncourt S; Saunders N; Robinot R; Auguste L; Rajah MM; Kervevan J; Jeger-Madiot R; Staropoli I; Planchais C; Mouquet H; Buchrieser J; Schwartz O; Chakrabarti LA
J Virol; 2022 Oct; 96(19):e0130122. PubMed ID: 36121299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
